Seres Therapeutics Faces Delisting Concerns
Ticker: MCRB · Form: 8-K · Filed: Apr 23, 2024 · CIK: 1609809
| Field | Detail |
|---|---|
| Company | Seres Therapeutics, Inc. (MCRB) |
| Form Type | 8-K |
| Filed Date | Apr 23, 2024 |
| Risk Level | high |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, compliance, stock-exchange
TL;DR
SERES is on the chopping block - might get delisted soon.
AI Summary
Seres Therapeutics, Inc. filed an 8-K on April 23, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of April 19, 2024. The company is incorporated in Delaware and its principal executive offices are located at 101 Cambridgepark Drive, Cambridge, MA.
Why It Matters
This filing indicates potential issues with Seres Therapeutics' compliance with stock exchange listing requirements, which could lead to the company's stock being delisted.
Risk Assessment
Risk Level: high — A notice of delisting directly impacts the stock's tradability and investor confidence, posing a significant risk.
Key Players & Entities
- Seres Therapeutics, Inc. (company) — Registrant
- April 19, 2024 (date) — Date of earliest event reported
- April 23, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 101 Cambridgepark Drive, Cambridge, MA 02140 (address) — Address of Principal Executive Offices
FAQ
What specific listing rule or standard has Seres Therapeutics failed to satisfy?
The filing states 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard' but does not specify the exact rule or standard in the provided text.
What is the exact date the company became aware of this delisting issue?
The earliest event reported is April 19, 2024.
Has Seres Therapeutics taken any steps to address the delisting concern?
The provided text does not contain information about any steps taken by the company to address the delisting concern.
What is the ticker symbol for Seres Therapeutics, Inc.?
The ticker symbol is not explicitly mentioned in the provided text, but the SEC file number is 001-37465.
When was the company formerly known as Seres Health, Inc.?
The date of the name change from Seres Health, Inc. to Seres Therapeutics, Inc. was June 3, 2014.
Filing Stats: 1,178 words · 5 min read · ~4 pages · Grade level 15 · Accepted 2024-04-23 07:00:54
Key Financial Figures
- $0.001 — ich registered Common stock, par value $0.001 per share MCRB The Nasdaq Stock Mar
- $1.00 — e "Common Stock"), had closed below the $1.00 per share minimum bid price requirement
Filing Documents
- d804228d8k.htm (8-K) — 27KB
- 0001193125-24-105862.txt ( ) — 144KB
- mcrb-20240419.xsd (EX-101.SCH) — 3KB
- mcrb-20240419_lab.xml (EX-101.LAB) — 17KB
- mcrb-20240419_pre.xml (EX-101.PRE) — 11KB
- d804228d8k_htm.xml (XML) — 3KB
Forward-Looking Statements Disclaimer
Forward-Looking Statements Disclaimer This Current Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the Company's intent or ability to transfer the listing of its common stock to The Nasdaq Capital Market, regain compliance with any applicable Nasdaq listing requirements, implement a reverse stock split, or the timing of any of the foregoing. These forward-looking statements are based on the Company's management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to the factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), on March 5, 2024, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERES THERAPEUTICS, INC. Date: April 23, 2024 By: /s/ Thomas J. DesRosier Name: Thomas J. DesRosier Title: Executive Vice President and Chief Legal Officer